[Dynamic monitoring risk of anti-hepatoma new drug development].
Risk monitoring of new Chinese patent anti-hepatoma drugs is tracking recognized risks and residual risks, identifying emerging risk and ensure the implementation of the plan, estimating the process of reducing effectiveness. The paper is mainly through understanding the status of Chinese patent anti-hepatoma drugs, the content, characteristic and analysis method of dynamic risk monitoring, and then select the risk control indicators, collect risk information. Finally, puts forward the thought of anti-hepatoma drugs listed evaluation in our country, and try to establish the model of dynamic risk management of anti-hepatoma drugs.
Jing
J
Zhang
Wei
W
Fan
Hong-Fa
HF
Li
Shu-Li
SL
Man
Zhen
Z
Liu
Wen-Yuan
WY
Gao
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D055808:Drug Discovery / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration; D004335:Drug and Narcotic Control / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing
D000972:Antineoplastic Agents, Phytogenic; D004365:Drugs, Chinese Herbal